Catalent, Inc. (NYSE:CTLT) Stock Position Increased by Raymond James & Associates

Raymond James & Associates increased its position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 23.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 149,279 shares of the company's stock after purchasing an additional 28,106 shares during the quarter. Raymond James & Associates owned approximately 0.08% of Catalent worth $6,707,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Cetera Advisor Networks LLC increased its holdings in shares of Catalent by 7.1% in the first quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company's stock valued at $217,000 after purchasing an additional 130 shares during the last quarter. Mackay Shields LLC increased its stake in shares of Catalent by 0.6% in the 1st quarter. Mackay Shields LLC now owns 25,749 shares of the company's stock worth $2,856,000 after acquiring an additional 149 shares during the last quarter. Wetherby Asset Management Inc. raised its holdings in shares of Catalent by 5.1% during the 1st quarter. Wetherby Asset Management Inc. now owns 5,023 shares of the company's stock worth $557,000 after acquiring an additional 243 shares during the period. Nissay Asset Management Corp Japan ADV raised its holdings in shares of Catalent by 1.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 21,164 shares of the company's stock worth $953,000 after acquiring an additional 252 shares during the period. Finally, Covestor Ltd boosted its position in shares of Catalent by 84.9% during the 1st quarter. Covestor Ltd now owns 562 shares of the company's stock valued at $62,000 after acquiring an additional 258 shares during the last quarter.

Catalent Stock Up 0.5 %

Catalent stock traded up $0.26 during trading on Tuesday, reaching $56.95. The stock had a trading volume of 989,959 shares, compared to its average volume of 2,714,036. Catalent, Inc. has a 52-week low of $31.45 and a 52-week high of $67.54. The business has a 50 day moving average price of $56.77 and a 200 day moving average price of $47.67. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34. The stock has a market cap of $10.29 billion, a PE ratio of -8.37, a P/E/G ratio of 6.12 and a beta of 1.20.

Catalent (NYSE:CTLT - Get Free Report) last issued its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.22). The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business's revenue for the quarter was down 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.62 EPS. On average, analysts predict that Catalent, Inc. will post 0.28 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on CTLT. StockNews.com began coverage on shares of Catalent in a research report on Wednesday, April 3rd. They set a "sell" rating on the stock. Stephens reiterated an "equal weight" rating and set a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. Royal Bank of Canada reissued a "sector perform" rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. Barclays upped their target price on shares of Catalent from $45.00 to $47.00 and gave the company an "equal weight" rating in a research report on Thursday, January 25th. Finally, UBS Group reissued a "neutral" rating and issued a $63.50 price target (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $52.46.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.